Product Description: Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. /[2]Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966.
CAS Number: 1629760-28-6
Molecular Weight: N/A
Compound Purity: 99.76
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
